Livforsakringsbolaget Skandia Omsesidigt trimmed its position in Danaher Co. (NYSE:DHR) by 20.2% in the 4th quarter, Holdings Channel reports. The firm owned 9,486 shares of the conglomerate’s stock after selling 2,400 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Danaher were worth $880,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in DHR. GQG Partners LLC purchased a new position in shares of Danaher in the second quarter worth about $101,000. Zions Bancorporation raised its stake in shares of Danaher by 118.3% in the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after purchasing an additional 667 shares during the last quarter. Patten Group Inc. raised its stake in shares of Danaher by 262.3% in the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after purchasing an additional 3,497 shares during the last quarter. Monetary Management Group Inc. raised its stake in shares of Danaher by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after purchasing an additional 150 shares during the last quarter. Finally, Acrospire Investment Management LLC raised its stake in shares of Danaher by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after purchasing an additional 1,100 shares during the last quarter. Hedge funds and other institutional investors own 76.11% of the company’s stock.

Shares of Danaher Co. (DHR) opened at $100.56 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00. Danaher Co. has a 1-year low of $78.97 and a 1-year high of $100.88. The company has a market capitalization of $69,950.03, a P/E ratio of 25.85, a price-to-earnings-growth ratio of 2.18 and a beta of 1.02.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, beating the consensus estimate of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The company had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.47 billion. During the same period last year, the company earned $0.87 earnings per share. Danaher’s quarterly revenue was up 9.6% compared to the same quarter last year. equities research analysts anticipate that Danaher Co. will post 3.99 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be issued a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s payout ratio is currently 16.52%.

Several research analysts recently weighed in on the company. Morgan Stanley lifted their price target on Danaher from $95.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday, October 20th. Credit Suisse Group lifted their price target on Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a research report on Thursday, October 5th. Goldman Sachs Group reiterated a “neutral” rating and set a $83.00 price target on shares of Danaher in a research report on Tuesday, September 26th. Finally, Citigroup lifted their price target on Danaher to $107.00 and gave the company a “buy” rating in a research report on Friday, December 15th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $95.86.

In other news, CFO Daniel L. Comas sold 88,184 shares of Danaher stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $91.02, for a total value of $8,026,507.68. Following the sale, the chief financial officer now directly owns 227,816 shares of the company’s stock, valued at $20,735,812.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Donald J. Ehrlich sold 10,578 shares of Danaher stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total value of $960,693.96. Following the completion of the sale, the director now directly owns 104,621 shares in the company, valued at $9,501,679.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/21/danaher-co-dhr-shares-sold-by-livforsakringsbolaget-skandia-omsesidigt.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.